Enliven Therapeutics, Inc. (NASDAQ:ELVN) director Rahul D. Ballal has recently engaged in transactions involving the company's common stock, according to a new SEC filing. On April 1, 2024, Ballal sold a total of 3,237 shares at an average price of $19.0789, netting a total of approximately $61,758.
The transactions occurred through a pre-arranged 10b5-1 trading plan, which allows company insiders to set up a trading plan for selling stocks they own in accordance with the insider trading laws. The sold shares were executed in multiple trades with prices ranging from $19.00 to $19.065. Ballal has agreed to provide full information regarding the number of shares sold at each price upon request.
In addition to the sale, Ballal also acquired shares through the exercise of options. Specifically, Ballal exercised options to buy 94 shares at $12.60 each and another set of options to buy 3,143 shares at $5.52 each. The total value of the shares acquired from these option exercises amounted to $18,533, with the price paid per share ranging between $5.52 and $12.6.
After these transactions, Ballal's direct ownership in Enliven Therapeutics stands at 22,341 shares of common stock. The recent filing also notes that the number of shares beneficially owned by Ballal reflects a previous 1-for-4 reverse stock split of the issuer's common stock.
Investors and followers of Enliven Therapeutics may view the full details of the transactions on the SEC's website, as the Form 4 filing provides transparency into the trading activities of the company's directors and executive officers.
InvestingPro Insights
Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been navigating a complex financial landscape, as evidenced by recent insider transactions and market performance metrics. Director Rahul D. Ballal's recent stock sale coincides with a notable period for the company, which has been characterized by a mix of financial strengths and challenges.
An InvestingPro Tip highlights that Enliven Therapeutics holds more cash than debt on its balance sheet, which could provide a cushion against market volatility and financial strain. Additionally, the company's liquid assets exceed its short-term obligations, suggesting a robust short-term financial health. These factors are particularly relevant for investors considering the company's ability to manage its finances in uncertain economic times.
On the flip side, Enliven Therapeutics does not pay a dividend, which may be a consideration for income-focused investors. Moreover, the company has struggled with profitability, not having turned a profit over the last twelve months as of Q1 2023. This is reflected in the company's negative P/E Ratio, which stood at -9.14, and an even more pronounced adjusted P/E Ratio for the last twelve months as of Q4 2023 at -10.91. The negative earnings also impacted the company's return on assets, which was reported at -40.31% for the same period. Despite these challenges, the company has experienced a strong return over the last three months, with a price total return of 27.42%, and an even larger uptick over the last six months at 36.49%.
For those looking to delve deeper into Enliven Therapeutics' financials and market performance, InvestingPro offers additional insights. There are 6 more InvestingPro Tips available for ELVN at https://www.investing.com/pro/ELVN, which may provide further guidance on the company's financial health and stock performance. To access these tips and more detailed analytics, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
The recent transactions by Ballal, combined with the company's current financial metrics, paint a nuanced picture of Enliven Therapeutics' position in the market. For investors, these insights can help in making informed decisions about the potential risks and opportunities associated with investing in ELVN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.